Kanavig (Moxifloxacin Hydrochloride)

Moxifloxacin inhibits two essential bacterial enzymes, DNA gyrase (topoisomerase II) and topoisomerase IV. By blocking these enzymes, the drug prevents bacterial DNA replication and transcription, leading to bacterial cell death. This mechanism provides rapid bactericidal activity against a wide range of Gram‑positive and Gram‑negative ocular pathogens.

The dosing regimen for Kanavig is determined by the prescribing clinician based on the specific infection, severity, and patient factors. Typically, the prescriber will advise the number of drops per eye and the frequency of administration, and patients should follow the exact instructions provided on the prescription label.

Safety data for Kanavig in pregnancy and lactation are limited. Health‑care providers should evaluate the potential benefits against possible risks before prescribing to pregnant or nursing women. If treatment is essential, the prescriber may consider the lowest effective dose and monitor the patient closely.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Kanavig. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Kanavig’s active ingredient, moxifloxacin, offers a broader spectrum of activity and higher potency against many resistant strains compared with older fluoroquinolone eye drops such as ciprofloxacin. It also provides good penetration into corneal tissue, which can be advantageous in treating keratitis, while maintaining a similar safety profile.

Kanavig should be stored at room temperature, preferably below 25 °C, in its original container. Keep the bottle protected from light and moisture, and avoid freezing. Once opened, discard any remaining solution after the period indicated on the label, even if some product remains.

Kanavig is applied as eye drops. The patient should wash their hands, tilt the head back, pull down the lower eyelid to create a small pocket, and instill the prescribed number of drops into the conjunctival sac. The eye should be closed gently for a few seconds to allow absorption, and contact lenses should be removed before use and re‑inserted only after the medication is cleared.

Serious risks, although rare, include severe allergic reactions such as contact dermatitis, corneal ulceration or perforation, and sudden loss of visual acuity. Patients should seek immediate medical attention if they experience intense eye pain, worsening redness, swelling, or any sudden change in vision while using Kanavig.

Kanavig should not be used by individuals with a known hypersensitivity to moxifloxacin, other fluoroquinolones, or any excipients in the formulation. It is also contraindicated in patients who are currently using systemic fluoroquinolones when additive toxicity is a concern, and in those for whom the prescriber determines that the risks outweigh the benefits.